Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

/p>

The Group operating result for the first nine months of 2007 amounted to EUR (36.7) million (2006: EUR (25.0) million). The decline is a result of the reduced revenue and gross profit levels, high investment in the advancement and enhancement of Evotec's proprietary pipeline (R&D expenses: +22%) and a related 19% increase in SG&A expenses, including transaction costs for divestments and acquisitions. For the first nine months of 2007, net loss remained on last year's level at EUR 23.6 million (2006: EUR 24.6 million). This is due to a non-operating profit from the divestment of Evotec Technologies GmbH to PerkinElmer (EUR 11.2 million), the divestment of shares of Direvo Biotech AG (EUR 0.5 million) and high interest income due to increased cash levels (EUR 1.0 million).

In total, cash and cash equivalents at the end of September 2007 on a proforma basis including proceeds from the divestment of Evotec's Chemical Development Business to Aptuit, Inc. (approximately EUR 46.4 million) amounted to EUR 106.8 million. The reported cash position excluding the proceeds from the divestment to Aptuit was EUR 60.4 million (December 31, 2006: EUR 78.1 million). The decrease mainly results from high R&D investment and an increase in working capital by EUR 10.6 million compared to the extraordinarily low level of working capital recorded at year-end 2006.

Corporate Events:

- Compelling proof-of-concept data achieved in two Phase II studies with insomnia drug candidate EVT 201

- In adult insomniacs (first study), EVT 201 showed highly statistically significant effects on sleep onset and maintenance and was free of any subjective evidence of hang-over, thereby revealing a competitive drug profile

- Top-line results of the second study in elderly insomniacs confirmed the robust effects seen in the first study and indicate that the same doses show hypnotic efficacy in the elderly as well as positive effects on day-time performance (less sleepiness)
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Bi-Biomics today announced a discovery made possible ... improvement in histological quality provided the detail necessary ... daughter cells. , After processing with Ultralight Histology’s ... 1000-1600x using light microscopy. Phylogenetic and histologic ... cells displayed predominant binary features --- one nucleus ...
(Date:3/5/2015)... 5, 2015  UBM Medica US announces that ... online community to help oncologists and other clinicians ... available regarding the use of targeted therapies and ... March is National Kidney Cancer Awareness ... adjuvant treatment options for renal cell carcinoma (RCC) ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/4/2015)... March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... for the: , 3.75% Convertible Senior Notes due ... common stock per $1,000 principal amount or approximately $5.72 per ... for the note is adjusted in connection with the regular ... to all stockholders who own shares of PDL on March 5, ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... Fair Political,Practices Commission, SANTA MONICA, Calif., Nov. 21 ... resign from the board for,violating conflict of interest rules, ... Reed intervened and attempted to influence the awarding ... Burnham Institute, where Reed is,president and chief executive., ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... during the 19th Annual Piper Jaffray,Health Care Conference ... Eastern,Time. The presentation will be webcast from The ... the Investor Relations tab at http://www.alexza.com ,or ...
... Incorporated,(Nasdaq: VPHM ) today announced that Vincent ... of ViroPharma, will present,at the Lazard Capital Markets ... Tuesday, November 27, 2007. The conference is being ... also announced that Michel de Rosen, president and ...
Cached Biology Technology:California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 2California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 319th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2ViroPharma to Present at Two Upcoming Healthcare Conferences 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... trees, which are a main resource for desert people ... hyper-arid Eastern Desert of Egypt. , In places more ... 1965 and 2003, while almost no new trees have ... tree mortality seems not to be climate, but commercial ...
... nocturnally migrating songbirds, while venturing into the unfamiliar night ... at least release anti-predator vigilance thanks to the concealment ... scientists ?published this week in PLoS ONE ?shows that ... passerines. , A unique creature is indeed capable ...
... found on the islands of Borneo and Sumatra is an ... originally thought to be the same species as the one ... conducted at the U.S. National Cancer Institute shows that the ... the differences between other large cat species like lions, tigers, ...
Cached Biology News:Bats prey on nocturnally migrating songbirds 2Bats prey on nocturnally migrating songbirds 3Bats prey on nocturnally migrating songbirds 4New species declared: Clouded leopard on Borneo and Sumatra 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
TTC4 Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
...
Biology Products: